GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurobiological Technologies Inc (OTCPK:NTII) » Definitions » Capex-to-Operating-Income

Neurobiological Technologies (Neurobiological Technologies) Capex-to-Operating-Income : 0.00 (As of Sep. 2009)


View and export this data going back to 1994. Start your Free Trial

What is Neurobiological Technologies Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Neurobiological Technologies's Capital Expenditure for the three months ended in Sep. 2009 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2009 was $5.15 Mil.

Hence, Neurobiological Technologies's Capex-to-Operating-Income for the three months ended in Sep. 2009 was 0.00.


Neurobiological Technologies Capex-to-Operating-Income Historical Data

The historical data trend for Neurobiological Technologies's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurobiological Technologies Capex-to-Operating-Income Chart

Neurobiological Technologies Annual Data
Trend Jun00 Jun01 Jun02 Jun03 Jun04 Jun05 Jun06 Jun07 Jun08 Jun09
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Neurobiological Technologies Quarterly Data
Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Neurobiological Technologies's Capex-to-Operating-Income

For the Biotechnology subindustry, Neurobiological Technologies's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurobiological Technologies's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurobiological Technologies's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Neurobiological Technologies's Capex-to-Operating-Income falls into.



Neurobiological Technologies Capex-to-Operating-Income Calculation

Neurobiological Technologies's Capex-to-Operating-Income for the fiscal year that ended in Jun. 2009 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.002) / 3.684
=0.00

Neurobiological Technologies's Capex-to-Operating-Income for the quarter that ended in Sep. 2009 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / 5.148
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neurobiological Technologies  (OTCPK:NTII) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Neurobiological Technologies Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Neurobiological Technologies's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurobiological Technologies (Neurobiological Technologies) Business Description

Traded in Other Exchanges
N/A
Address
2010 Crow Canyon Place, Suite 100, San Ramon, CA, USA, 94583
Neurobiological Technologies Inc is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.
Executives
Ariel Warszawski 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Ryan Heslop 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Management Co Gp, Llc 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Fvp Gp, Llc 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Value Partners, Lp 10 percent owner 426 PINEVILLE ROAD, UNIT 1, NEWTOWN PA 18940
Fvp Master Fund Lp 10 percent owner FVP GP LLC, 551 FIFTH AVENUE, 36TH FLOOR, New York NY 10176
John B Stuppin director
Abraham E Cohen director 500 SEVENTH AVE 10TH FL, C/O AXONYX INC, NEW YORK NY 10018
Abraham D Sofaer director HOOVER INSTITUTION, STANFORD UNIVERSITY, STANFORD CA 94305-6010
Biotechnology Value Fund L P other: Direct Beneficial Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: Direct Beneficial Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Investments Llc other: Direct Beneficial Owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104

Neurobiological Technologies (Neurobiological Technologies) Headlines